Clinical trial
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following…
NCT00258765 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00258765 |
|---|---|
| Title | Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy. |
| Official title | A Phase IIb Randomised Clinical Trial of the Tolerability, Safety and Efficacy of Adjuvant Docetaxel-Zoledronic Acid After Prostatectomy for High-risk Early Prostate Cancer (AD-ZAP). |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic Acid, Docetaxel |
| Enrollment | 1 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2006 |
| First posted | Nov 28, 2005 |
| Last update posted | Apr 26, 2010 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: